DelNova extends scientific platform to natural deodorant supported by dermatologist Dr. Kathy Fields

DelNova today announces SECCO, patent-pending aluminum-free deodorant that applies sweat-inhibition science to personal care, backed by dermatologist Dr. Kathy Fields.

CHICAGO, Oct. 6, 2026 /PRNewswire/ -- Today DelNova is announcing a paradigm shift in personal care with SECCO, translating scientific principles of sweat inhibition to create a premium, clean, natural, aluminum-free product. DelNova, Inc. debunks the misconception that consumers must accept inferior protection in their daily hygiene routine or face potential health concerns.

DelNova's biopharma story evolves to clean beauty within its new division, DelNaturals. DelNaturals is redefining personal hygiene with its patent-pending aluminum-free deodorant SECCO, designed to target perspiration at its source while delivering long-lasting performance.

Rather than competing as another clean beauty brand, DelNaturals is creating a new product category. Health-conscious consumers want clean, synthetic chemical-free, metal-free deodorants but face a basic dilemma: natural options only mask or mitigate odor, with little attention to wetness. They do not meaningfully reduce sweat. That gap between clean claims and real performance is frustrating a growing market segment.

DelNaturals closes the gap by applying scientific discovery to deliver a new standard of performance. With SECCO, there is no need for consumers to compromise between natural and product performance. SECCO will be a first-in-class natural deodorant formulated with premium skincare ingredients to deliver sweat-inhibiting performance without aluminum or metal salts. The technology is proprietary and patent-pending, originating from DelNova's clinical-stage biopharma platform. Starting from known scientific mechanisms and a consumer gap flagged by Dr. Fields, the novel formulation is powered by a proprietary ingredient blend sourced from plants.

Legacy brands have failed to advance beyond aluminum-containing antiperspirants for over a century. DelNaturals is poised to build on its scientific credibility and network of medical professionals to educate consumers, attract investors, and establish third-party validation before widespread commercial adoption.

Positioned for Strategic Partners and Investors

"DelNaturals is seeking partners who recognize the value of IP-protected innovation in the clean beauty space," says Mary Gardner, CEO & Founder. The personal care sector is undergoing consolidation around brands capable of delivering both clean credentials and credible scientific differentiation. Investors and strategic partners increasingly prioritize platforms with defensible intellectual property, translational research foundations, and leadership teams experienced in regulated product development.

DelNaturals is positioned within this emerging landscape. The company's patents, scientific heritage, and disciplined R&D approach create a foundation for expansion into adjacent premium personal care categories. The deodorant platform represents the first consumer-facing application of the company's broader technology portfolio.

""The market does not need another fragrance story. It needs a product that meets expectations for feeling fresh and dry. Dr. Fields' involvement is not only a significant endorsement of DelNova's credibility. Dr. Fields' participation adds category-building expertise from two of the most commercially successful dermatologist-founded brands of the past three decades and expands DelNova's access to clinical and consumer networks in skincare," says Mary Gardner, CEO & Founder.

About Dr. Kathy Fields
Dr. Kathy A. Fields is one of the most widely recognized dermatologists and entrepreneurs in modern skincare. She is the co-creator of Proactiv and co-founder of Rodan + Fields, two of the most influential skincare brands of the past three decades. She is a board-certified dermatologist, an Assistant Clinical Professor of Dermatology at UCSF, and an Adjunct Clinical Associate Professor at Stanford University.

Dr. Fields' career spans therapeutic dermatology, consumer skincare innovation, and leadership in science-based brand building. She has been repeatedly recognized by Forbes and is known for advancing clinically informed skincare solutions that reach broad consumer audiences.

About DelNova, Inc. and DelNaturals
DelNova Inc. is a biopharma startup with a proven track record of innovation targeting unaddressed market needs and technology gaps. ReViVox, the company's lead therapeutic asset, is positioned to serve a global botulinum toxin market measured in the multi-billion-dollar range. There is a well-documented absence of an approved, locally administered reversal agent for off-target paralysis, including eyelid and brow ptosis. The new structure is intended to create value-creation paths from a single scientific franchise.

DelNaturals, its newly created division, is designed to generate a nearer-term commercial platform in premium personal care while reinforcing DelNova's intellectual-property portfolio and dermatology relationships. SECCO deodorant will be the first product launch (www.seccolab.com).

Contact
Mary Gardner
CEO & Founder, DelNova, Inc.
224 730 1621
[email protected]
www.delnova.net

SOURCE DelNova, Inc.